Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1344997-62-1

Post Buying Request

1344997-62-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1344997-62-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1344997-62-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,4,4,9,9 and 7 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1344997-62:
(9*1)+(8*3)+(7*4)+(6*4)+(5*9)+(4*9)+(3*7)+(2*6)+(1*2)=201
201 % 10 = 1
So 1344997-62-1 is a valid CAS Registry Number.

1344997-62-1Downstream Products

1344997-62-1Relevant articles and documents

Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P1)

Ren, Feng,Deng, Guanghui,Wang, Hailong,Luan, Linbo,Meng, Qinghua,Xu, Qiongfeng,Xu, Heng,Xu, Xuesong,Zhang, Haibo,Zhao, Baowei,Li, Chengyong,Guo, Taylor B.,Yang, Jiansong,Zhang, Wei,Zhao, Yonggang,Jia, Qiantao,Lu, Hongtao,Xiang, Jia-Ning,Elliott, John D.,Lin, Xichen

experimental part, p. 4286 - 4296 (2012/07/03)

A novel series of 1,2,4-thiadiazole compounds was discovered as selective S1P1 agonists. The extensive structure-activity relationship studies for these analogues were reported. Among them, 17g was identified to show high in vitro potency with reasonable free unbound fraction in plasma (Fu > 0.5%), good brain penetration (BBR > 0.5), and desirable pharmacokinetic properties in mouse and rat. Oral administration of 1 mg/kg 17g resulted in significant peripheral lymphocytes reduction at 4 h after dose and rapid lymphocytes recovery at 24 h. 17g showed a transient lymphopenia profile in the repeated dose study in mouse. In addition, 17g also demonstrated efficacy comparable to that of FTY720 (1) in the mouse EAE model of MS.

COMPOUNDS AS AGONISTS OF S1P1 RECEPTORS

-

, (2011/11/12)

Compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by S1P1 receptors.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1344997-62-1